Oryzon Genomics SA

Oryzon Genomics has a current ratio of 1.95, indicating that it has 1.95 times more current assets than current liabilities, which is a relatively strong liquidity position for a biopharmaceutical firm in clinical development. However, the company's free cash flow is negative at -13.45 million EUR, and its operating cash flow is also negative at -2.36 million EUR, suggesting that it is not generating positive cash from operations and is likely relying on financing activities to fund its operations. The company's cash and equivalents amount to 3.00 million EUR, which is significantly lower than its long-term debt of 7.63 million EUR, resulting in a negative net cash position. In terms of profitability, Oryzon Genomics is currently unprofitable, with a net loss of 2.61 million EUR and an operating loss of 5.71 million EUR. The company's return on equity is -2.21%, and its return on assets is -1.80%, both of which are negative and indicate poor capital efficiency and asset utilization. These metrics are below the typical performance of companies in the biotechnology industry, which often experience early-stage losses but are expected to show signs of improving returns as they progress through clinical trials and toward commercialization. Oryzon Genomics' revenue is currently reported at 0.0 EUR, and the company does not provide segment-specific revenue data in the latest financial snapshot. The company's geographic exposure is not explicitly detailed, but as a Spain-based firm, it is likely to have a significant portion of its operations and market exposure within Europe. The lack of revenue and segment data makes it difficult to assess the company's diversification and potential for growth in different markets. The company's growth trajectory is uncertain, as it has not generated any revenue and is experiencing significant losses. The outlook for the current fiscal year does not provide specific numeric deltas for revenue growth, but the company's ongoing clinical trials for iadademstat and vafidemstat may represent potential catalysts for future revenue if these compounds progress successfully through development and receive regulatory approval. The company's capital expenditures are negative at -10.98 million EUR, which may indicate a reduction in investment in physical assets or a reclassification of expenses. The risk assessment for Oryzon Genomics highlights a medium liquidity risk and a low dilution risk. The company's liquidity risk is primarily due to its negative net cash position after accounting for total debt, which could limit its ability to fund operations without additional financing. The low dilution risk suggests that the company is not expected to issue a large number of new shares in the near term, which is a positive sign for existing shareholders. However, the company's reliance on external financing to fund its operations and clinical trials remains a key risk factor. Recent events and disclosures related to Oryzon Genomics include the ongoing clinical trials for its LSD1 inhibitors, iadademstat and vafidemstat, which are in Phase II trials for oncological and neurological indications. The company has also disclosed its financial position, including its negative cash flow and reliance on financing activities, in its latest financial snapshot. These developments are critical for investors to monitor, as they may impact the company's future financial performance and valuation.